BK polyomavirus (BKPyV) has recently been postulated as an emerging opportunistic pathogen of the human central nervous system (CNS), but it is not known whether specific strains are associated with the neurotropic character of BKPyV. The presence of BKPyV large T-antigen DNA was examined in 2406 cerebrospinal fluid (CSF) samples from neurological patients with suspected JC polyomavirus infection. Twenty patients had a large T-antigen DNA-positive specimen. The non-coding control region (NCCR) of the BKPyV strains amplified from CSF from these 20 patients, strains circulating in renal and bone marrow transplant recipients and from healthy pregnant women was sequenced. The archetypal conformation was the most prevalent in all groups and 14 of the neurological patients harboured archetypal strains, while the remaining six patients possessed BKPyV with rearranged NCCR similar to previously reported variants from non-neurological patients. Transfection studies in Vero cells revealed that five of six early and four of six late rearranged promoters of these CSF isolates showed significantly higher activity than the corresponding archetypal promoter. From seven of the neurological patients with BKPyV DNApositive CSF, paired serum samples were available. Five of them were negative for BKPyV DNA, while serum from the remaining two patients harboured BKPyV strains with archetypal NCCR that differed from those present in their CSF. Our results suggest that NCCR rearrangements are not a hallmark for BKPyV neurotropism and the dissemination of a rearranged NCCR from the blood may not be the origin of BKPyV CNS infection.
INTRODUCTION
BK polyomavirus (BKPyV) is a small dsDNA virus that belongs to the family Polyomaviridae which also contains the human species JC (JCPyV) (Padgett et al., 1971) , WU (Gaynor et al., 2007) , KI (Allander et al., 2007) , Merkel cell polyomavirus (Feng et al., 2008) , trichodysplasia spinulosaassociated polyomavirus (van der Meijden et al., 2010) , human polyomaviruses 6, 7 and 9 (Schowalter et al., 2010; Scuda et al., 2011) . BKPyV is widely distributed in the human population and a seroprevalence rate of 82 % in healthy adult blood donors has been reported (Kean et al., 2009 ). BKPyV's primary asymptomatic infection usually occurs during early childhood (3-4 years) and the respiratory (Sundsfjord et al., 1994) and oral-faecal (BofillMas et al., 2000) routes have been postulated. Vertical transmission soon after birth or during pregnancy has been suggested (Boldorini et al., 2011) . After primary infection, latency is established mostly in the urogenital tract (Arthur et al., 1989) , but also in mononuclear cells (Dörries et al., 1994; Tornatore et al., 1992) and in the central nervous system (CNS) (Vago et al., 1996) . In fact, BKPyV DNA has been detected in brain tissue and cerebrospinal fluid (CSF) of both immunocompetent and immunocompromised subjects with or without neurological symptoms (BehzadBehbahani et al., 2003a, b; Voltz et al., 1996) . Reactivation of BKPyV is not uncommon and is frequently associated with asymptomatic urinary shedding in diabetic patients, increasing age and during pregnancy (Bendiksen et al., 2000; Zhong et al., 2007) . However, pathological reactivation is generally related to patients under severe immunosuppression such as renal transplant and bone marrow transplant recipients where BKPyV is the aetiological agent of nephropathy (PVAN) and haemorrhagic cystitis (HC), respectively. Moreover, although the neurotropic character is mostly related to JCPyV, which is strongly associated to progressive multifocal leukoencephalopathy (PML), BKPyV has been postulated as an emerging opportunistic pathogen of the CNS (Lopes da Silva, 2011a). During almost 20 years, only 26 cases of BKPyV-associated neurological infections have been reported (Behre et al., 2008; Behzad-Behbahani et al., 2003a, b; Bratt et al., 1999; Cabrejo et al., 2005; Ferrari et al., 2008; Friedman & Flanders, 2006; Garavelli & Boldorini, 2002; Hedquist et al., 1999; Hix et al., 2004; Jørgensen et al., 2003; Kinnaird & Anstead, 2010; Lesprit et al., 2001 ; Lopes da Silva et al., 2011; Stoner et al., 2002; Vallbracht et al., 1993; Vidal et al., 2007; Voltz et al., 1996) . BKPyV-associated neurological infection has been described in healthy individuals with reduced clinical involvement (Behzad-Behbahani et al., 2003a; Voltz et al., 1996) . However, most of the cases were immunosuppressed patients including AIDS patients, bone marrow transplant recipients suffering from encephalitis, or meningoencephalitis associated with renal impairment (Behre et al., 2008; BehzadBehbahani et al., 2003b; Bratt et al., 1999; Friedman & Flanders, 2006; Garavelli & Boldorini, 2002; Jørgensen et al., 2003; Kinnaird & Anstead, 2010; Lesprit et al., 2001 ; Lopes da Silva et al., 2011) .
In a previous study of our group, 20 new cases of BKPyVassociated neurological infection were reported (Bárcena-Panero et al., 2012) . DNA encoding the entire VP1 protein was successfully amplified from CSF from 14/20 of these patients and sequenced. Most of them suffered from AIDS and their neurological presentation was quite heterogenic, PML being the most common affection. VP1 sequences obtained from those patients were compared to the VP1 sequences detected in the blood of patients with other pathological conditions such as renal and bone marrow transplant recipients and in the urine of healthy pregnant women. Our results indicated that the mutations in BKPyV VP1 sequence seem to be frequent and independent of the development of BKPyV-associated neurological infection, suggesting that polymorphism in the VP1 protein does not appear to be the major determinant of neurotropism of BKPyV.
The BKPyV genome is organized into three functional domains: the hypervariable non-coding control region (NCCR) and the conserved early and late regions (Seif et al., 1979) . The NCCR contains the origin of replication (O-block) as well as the transcriptional control region that includes the promoter and enhancer for transcription of the early and late genes. The archetypal NCCR is arbitrarily divided into transcription factor binding regions O (142 bp), P (68 bp), Q (39 bp), R (63 bp) and S (63 bp) (Markowitz & Dynan, 1988; Moens et al., 1995) . BKPyV strains isolated from the urine of immunocompetent individuals and immunosuppressed patients contain the archetypal NCCR architecture known as WW (Bhattacharjee & Chakraborty, 2004; Chang et al., 1996; Egli et al., 2009; Flaegstad et al., 1991; Markowitz et al., 1991; Rubinstein & Harley, 1989) . However, after propagation in cell culture, strains showing rearranged NCCR take the place of BK WW strain (Flaegstad et al., 1991; Rubinstein et al., 1991; Sundsfjord et al., 1990) . Rearrangements consist of complete or partial duplications or deletions of the NCCR-blocks. BKPyV variants with rearranged NCCR have been detected in patients suffering from PVAN, HC and autoimmune diseases (Sugimoto et al., 1989; Sundsfjord et al., 1999) , but not in all patients (Anzivino et al., 2011; Boldorini et al., 2005; Carr et al., 2006; Olsen et al., 2006; Randhawa et al., 2003; Sharma et al., 2007) . In fact, the dominant structure of NCCR found in those patients corresponded to the archetypal form and therefore rearrangements seem to be neither necessary nor a sufficient condition for reactivation of the virus and the development of disease. In an elegant study, strains with rearranged NCCR were shown to emerge and substitute the WW variants that were predominant in the plasma of PVAN patients. Moreover, the appearance of the rearranged forms was correlated with significantly higher plasma viral load (Gosert et al., 2008) . In vitro studies demonstrated that rearranged variants identified in biopsy specimens of some of these patients displayed increased early gene expression, replication and cytopathology compared with WW. In a recent study, the main functional regions of the BKPyV genome (NCCR, early and late regions) were independently analysed and the NCCR region was shown to be the major determinant of replication in primary renal proximal tubule epithelial cells (Broekema et al., 2010) .
The NCCR architecture of BKPyV neurological strains has only been characterized in one leukaemia patient and in one AIDS patient, both suffering from meningoencephalitis and PVAN (Jørgensen et al., 2003; Stoner et al., 2002) . Variants with rearranged NCCR were identified in the CSF and brain of both patients, while the WW form was excreted in the urine. The presence of the rearranged strains exclusively in specimens from the CNS could be explained by viral adaptation to specific host tissues. However, because only two cases have been described, a larger number of patients should be studied.
BKPyV non-coding region in cerebrospinal fluid The aim of this study was to investigate if a specific NCCR conformation could be the determinant for neurotropism of BKPyV. As aforementioned, 20 neurological patients with a CSF sample positive for BKPyV large T-antigen (LTag) DNA were previously reported (Bárcena-Panero et al., 2012) . In the present study, the NCCR sequence of these neurological BKPyV isolates was determined and compared to the NCCR sequences from strains circulating in renal transplant recipients, bone marrow transplant patients and healthy pregnant women in order to elucidate whether rearrangements are involved in BKPyV neurotropism. Moreover, with the purpose of determining if those rearrangements confer better replication abilities to the neurological strains, the activities of the early and late promoters of the neurological rearranged strains were compared with those of the archetypal strain.
RESULTS
Amplification and sequencing of BKPyV NCCR DNA in neurological patients and in controls
Positive amplification of BKPyV NCCR DNA was achieved in the CSF of 20 neurological patients (NP1-NP20; Table  1 ) previously positive for BKPyV LT-ag DNA. Complete BKPyV NCCR sequences were obtained from 23 of 27 CSF samples and four of 22 sera specimens belonging to these 20 patients. Patients NP4 and NP15 had CSF samples that were PCR positive for both BKPyV and JCPyV LT-ag DNA, while CSF specimens of patients NP1, NP3, NP5, NP10 and NP18 were positive for herpes simplex virus (HSV), human herpesvirus 6 (HHV6), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and EBV, and EBV DNA, respectively.
Amplification and sequencing of BKPyV NCCR DNA were also completed for 37 blood samples and one serum sample from 38 of 44 kidney transplant recipients (referred to as RTR21-58; Table 2 ), five of five blood and 16 of 17 urine specimens from six bone marrow transplant recipients (referred to as BMT59-64; Table 2 ) and five urine samples from 5 of 11 pregnant women (referred to as PW1-5; Table 2 ).
NCCR architecture of BKPyV isolates in CSF from patients with neurological diseases
The BKPyV NCCR sequences obtained from the neurological patients and the pathological and non-pathological controls are shown in Tables 1 to 3 and Fig. 1 . Both rearranged and archetypal NCCR architectures could be observed in the CSF of the neurological patients but a specific NCCR conformation could not be associated with the BKPyV neurological strains.
Six patients (30 %) harboured rearranged variants RRA to RRF (GenBank accession nos JQ513609-JQ513614) in their CSF compared with the 7 of 44 (16 %) transplant recipients including 6 of 38 RTR and one of six BMT that contained BKPyV isolates with rearranged NCCR in their blood (RRG to RRM, GenBank accessions nos JQ513615-JQ513621) and to none of the five pregnant women. Although a higher frequency of rearrangements could be observed in the neurological patients differences were not statistically significant. The NCCR conformation of the rearranged forms is depicted in Fig. 1 . The architecture of these rearranged NCCR in the BKPyV strains present in the CSF of neurological patients is not unique because strains with similar NCCR anatomy have been previously reported in isolates from other patient groups (Table S1 , available in JGV Online). The archetypal NCCR contains a plethora of putative binding sites for transcription factors (Table S2 ). Due to the rearrangements, putative transcription factor binding sites are created or removed in the rearranged NCCRs (Table S3) . Rearranged variants RRA to RRF were isolated from five human immunodeficiency virus (HIV) positive (NP5, NP11, NP12, NP17 and NP20) and one HIV negative, immunosuppressed (NP7) patient. For patients NP5, NP17 and NP20 subsequent CSF specimens were available and sequence analysis of the BKPyV NCCR in these samples revealed conservation of the NCCR in the consecutive sample. Variants RRA, RRB and RRF showed a linear conformation (OPQRS) although large deletions of one or more of the blocks were detected, while variants RRC to RRE had non-linear conformations due to large deletions or/and duplications ( Fig. 1 ).
CSF of 14 neurological patients (NP1-4, NP6, NP8-10, NP13-16, NP18 and NP19) harboured strains with archetypal WW NCCR (Table 1) which was also the most common strain identified in different samples of both healthy individuals and pathological controls (Table 2 ). A total of 17 different WW strains (WWM to WWM17, GenBank accession nos JQ513592-JQ513608) were reported according to the point mutations (Tables 3 and 3a) . Variants WWM to WWM7 were detected in the CSF of neurological patients. WWM was the most frequently found variant, *Male or female, age in years.
DThe presence of other neurological viruses in the CSF of the neurological patients was evaluated by multiplex nested PCR of the LT-ag of BKPyV, JCPyV and SV40 and by a multiplex nested PCR that detects HSV, varicella-zoster virus (VZV), CMV, HHV6, EBV and human enteroviruses (EVs). dWWM variants contain the archetypal NCCR structure except for single point mutations, nucleotide insertions and deletions (see Table 3 ). §RR variants contain major modifications of the archetypal NCCR structure by duplications and/or deletions. Table 1 . cont.
BKPyV non-coding region in cerebrospinal fluid A. Bá rcena-Panero and others being identified in the CSF from nine of the patients with different clinical conditions (NP1, NP2, NP6, NP8, NP9, NP10, NP14, NP16 and NP19). Variants WWM5, WWM7 and WWM4, which were detected in the CSF of NP13 and NP18 and in the serum of NP5, respectively, were exclusive for the NP group. Remarkably, WWM17 was exclusively identified in the urine of pregnant healthy controls.
Early and late promoter activity of the rearranged NCCRs of the BKPyV strains detected in CSF differed significantly from archetypal WW NCCR Previous studies have shown that rearrangement in the NCCR changes the transcriptional strength of both the early and late promoters (Gosert et al., 2008; Markowitz et al., 1990; Moens et al., 1995) . The promoter activity of the rearranged NCCR of BKPyV variants isolated from CSF has not been tested so far (Jørgensen et al., 2003; Stoner et al., 2002) . Therefore, we compared the early and late transcriptional activities of the different NCCR variants characterized in BKPyV strains detected in CSF with that of the WW archetype. We also included the NCCR of the Dunlop strain as this isolate is often used in studies with BKPyV. This strain has an OPPPS NCCR structure (Moens et al., 1995) .
Except for variant RRA, all rearranged variants had significantly higher early promoter activity compared with the archetype (Fig. 2) . RRA possessed a significantly weaker promoter than the archetype. This variant has the linear OPQRS anatomy, but contains a 10 bp deletion in its Rblock. This deletion removes putative binding sites for several transcription factors (Table S3 ). The RRB and RRF variants also retain the linear OPQRS NCCR anatomy, but have deletions in the O, P, R and the R-and S-blocks, respectively. Both displayed higher (5.5-fold and 2.5-fold, respectively) early promoter activities than the archetype in this assay. Of the CSF-circulating BKPyV strains with nonlinear OPQRS NCCR anatomy, RRC had the highest early promoter activity (4.2 times higher than the archetype). This variant has an OPQRPQRS anatomy. RRD with a partial duplication of the P-block, and RRE with two incomplete P-blocks and a partial duplication of the Qblock also showed higher early promoter activity than archetypal NCCR. All variants had weaker early promoter activity than the Dunlop strain.
The late promoter activity of variants RRA to RRE and the Dunlop strain was significantly different from the archetypal, being 1.3-to 2.4-fold higher for the variants RRB, RCC, RRD and RRE and~30 % weaker for the variants RRA and the Dunlop strain.
NCCR architecture in the sera from neurological patients with BKPyV-positive CSF For seven neurological patients (NP3, NP5, NP6, NP8, NP9, NP13 and NP17), sera specimens paired to the CSF sample were available. No NCCR PCR product was obtained for the sera of five of these patients, while the sera of patients NP5 and NP8 harboured isolates with an archetypal NCCR (Table 1 ). In NP5, the rearranged form RRA was found in CSF, while an isolate with an archetypal NCCR (WWM4) was circulating in her serum. The serum of NP8 contained BKPyV with WWM2 NCCR, while WWM NCCR was detected in the CSF of this patient. In patient NP13, whose paired serum sample was negative, BKPyV NCCR DNA could be detected in two serum samples collected at later time points. Both of these contained BKPyV with WWM6 NCCR, while BKVPyV with WWM5 was present in her CSF. In the only patient with sera collected prior to the positive CSF (NP9), BKPyV DNA could not be detected in sera. Table 3 ). DRR variants contain major modifications of the archetypal NCCR structure by deletions or duplications (see Fig. 1 ). -T12 G20  C35-A36 T41  G84  A85  A102  T17  A18  A19  A23  T29  T31 G55 A58 C7  C2  G4  A5  A6  T9  C12  C38  G40  G41  C58  C3  G10  A18  T22  A23  G24  C29 A49-A50
BKPyV non-coding region in cerebrospinal fluid
WWM2 9 9 CCA G T C WWM3 16 9 AAT G T C C Dd WWM4 1 1 G WWM5 1 1 ATT G T C WWM6 7 4 WWM7 1 1 A G T C WWM8 3 2 G T C WWM9 4 4 AAT G T T C WWM10 1 1 G T C WWM11 1 1 CCA G C T C T C WWM12 1 1 C WWM13 1 1 AAT G T T C WWM14 2 2 AAT G C T C C D c WWM15 1 1 C WWM16 3 1 AAT G C T C C D WWM17 5 5 G T C RR §A 2 1 G T C C D RRB 1 1 AAT DA G A T T D D C D RRC 1 1 AAT G G T C C D RRD 1 1 CCA G C T C RRE 2 1 G T C D D RRF 2 1 C RRG 1 1 G T C RRH 1 1 CCA G T C RRI 1 1 CCA G C T C RRJ 1 1 CCA G C T C RRK 1 1 AAT G C C T G A C C D RRL 1 1 AAT G C T C C D RRM 1 1 AAT G T C C D *WWM2 G WWM3 A C T A ATA WWM4 WWM5 A A T G G WWM6 A WWM7 G WWM8 G A WWM9 A G G A G ATA WWM10 A WWM11 G WWM12 A WWM13 A G G G A G ATA WWM14 A C T G A G ATA WWM15 WWM16 A C T A ATA WWM17 G RR §A A C T A RRB A C D D D D A ATA RRC A C T A ATA RRD G RRE A D D D D D D D D D T A RRF D D D D D RRG G D D D D D D D D D D D D D D D D D D RRH G RRI G RRJ T G RRK A ATA RRL A C T A G ATA RRM A C T A ATA BKPyV non-coding region in cerebrospinal fluid
DISCUSSION
BKPyV is considered a nephrotropic virus that establishes a persistent, harmless infection in immunocompetent individuals (Hirsch & Steiger, 2003; Reploeg et al., 2001) . Although BKPyV resides mainly in the kidney after primary infection, it may also occupy other locations such as the CNS since it has been identified in the brain of normal individuals (De Mattei et al., 1995; Elsner & Dörries, 1992 Vago et al., 1996; Vallbracht et al., 1993; Vidal et al., 2007; Voltz et al., 1996) . Our study confirmed that BKPyV can occasionally be present in CSF from patients with neurological diseases. Clinical isolates typically possess point mutations or partial/complete duplications and deletions of the P-, Q-, R-and S-blocks which constitute the transcriptional control region (Moens & Van Ghelue, 2005; Sharma et al., 2007) . So far, the NCCR anatomy of two BKPyV strains isolated from CSF have been described; one from an AIDS patient and the other from a leukaemia patient with tubulointerstitial nephritis and meningoencephalitis (Jørgensen et al., 2003; Stoner et al., 2002) . Both isolates had a rearranged NCCR which made the authors speculate that these variants replicate better in neuronal cells. Similar to JCPyV, the aetiological agent of PML, it has been postulated that these strains with rearranged NCCR may be involved in the initiation and/or development of the neuropathological condition. While the archetypal NCCR sequence is consistently detected in the kidney and urine of immunocompromised and healthy individuals and is not infectious in tissue culture models, rearranged variants have been identified in the brain and other tissues of PML patients (Marshall & Major, 2010; Sabath & Major, 2002; White & Khalili, 2011) . Identically rearranged forms circulated in CSF and plasma of PML patients (Pfister et al., 2001) , suggesting that JCPyV can migrate from blood to brain before developing PML. The situation with BKPyV in neurological patients seems to A. Bá rcena-Panero and others differ from that of JCPyV in PML patients. CSF specimens from most patients contained non-rearranged archetypal strains and the rearrangements detected in the CSF of the neurological patients had a composition very similar to those observed in BKPyV isolates found in different biosamples from non-neurological patients (Table S1 ). This suggests that rearrangement of the NCCR does not seem to be a required condition for viral replication in neural tissue and for the development of BKPyVassociated neurological infection. These results are in agreement with previous studies proposing that rearrangements are not a prerequisite for the pathogenesis of other BKPyV-associated illnesses such as PVAN or HC (Boldorini et al., 2005; Carr et al., 2006; Randhawa et al., 2003; Sharma et al., 2007) .
On the other hand, for those patients with paired serum and CSF specimens, serum is generally negative for NCCR DNA (five of seven). Moreover, for the two patients whose serum and CSF were positive (NP5 and NP8), nonrearranged NCCR was detected (Table 1) and different NCCR sequences were identified in each compartment. A variant presenting a rearranged NCCR that confers its neurotropic abilities so it is able to spread from the bloodstream through the haematoencephalic barrier does not seem to be the origin of BKPyV-associated neurological infection. Local reactivation of the virus latent in brain seems to be a more plausible hypothesis for the initiation of the CNS infection though data provided in this study are not enough to confirm it.
Based on the point mutations, we have arbitrarily classified the archetypal sequences into 17 different variants with WWM being the most common sequence in the group of neurological patients. The strain WWM17 was exclusively identified in urine of healthy pregnant women confirming previous studies that had shown that pregnant women shed BKPyV with a non-rearranged archetypal NCCR with only subtle alterations, including point mutations or single nucleotide insertions or deletions (Bhattacharjee & Chakraborty, 2004; Chang et al., 1996; Markowitz et al., 1991) . All of these pregnant women are natives of Norway (Tromsø and Stavanger) (Bendiksen et al., 2000) , while the remaining patients all came from Spain. Interestingly, WWM17 was previously reported in the urine from a group of patients from Tromsø (WWT) (Sundsfjord et al., 1990) implying that WWM17 is circulating at least in that particular location.
The CSF of the remaining six patients harboured a nonarchetypal NCCR structure with major deletions and rearrangements. Three of the NCCR variants, RRA (NP5), RRB (NP7) and RRF (NP20), still had the linear OPQRS structure, but with major deletions in one or several of the blocks. Variants RRC (OPQRPQRS), RRD (OPPQRS) and RRE (OPQPQRS) had major duplications and deletions. Previous studies have shown that rearrangement in the NCCR changes the transcriptional strength of both the early and late promoters (Gosert et al., 2008; Markowitz et al., 1990; Moens et al., 1995) , but the promoter activity of the rearranged NCCR of BKPyV variants isolated from CSF has not been tested so far (Jørgensen et al., 2003; Stoner et al., 2002) . All CSF BKPyV isolates in this study had early promoter activities that differed significantly compared to the archetypal early promoter. Except for RRA whose activity was about 60 % of that of the archetypal early promoter, all rearranged variants had stronger early promoter activity than the archetype. RRA carries a small deletion in the R-block which removes putative binding sites for the transcription factors progesterone receptor A and B, SRY, Nkx2-1, PU.1, GABP, c-Ets-1, c-Ets-2, STAT5A, FOXN2, STAT1b, ELF-1, Elk-1, p300, STAT4, IRF-1, HMG I(Y) and R2 (Table S3 ). Whether any of these factors bind in vivo remains to be established. A functional progesterone responsive element has been identified in the region joining the terminal part of the S-block and the proximal part of the agnogene (Moens et al., 1994) , but not in the R-block. Deletions in the R-block were also observed in the RRB and RRF variants, but they contain additional deletions in other blocks (Fig. 1) . Dunlop had the strongest early promoter activity of the variants tested here. This strain has an NCCR characterized by a triplication of the P-block and complete deletion of the Q-and S-blocks (OPPPS) (Moens et al., 1995) , suggesting that additional P-blocks and/or deletion of Q-and/or R-blocks may strengthen early promoter activity. RRC, RRD and RRE also have additional P-block sequences, but retain (RRD) or partially or completely duplicate the Qand R-blocks (RRC and RRE). RRB was the variant that had highest early promoter activity of the BKPyV strains isolated Fig. 2 . Early and late promoter activity of the BKPyV variants isolated in CSF. The complete NCCR was cloned in both early and late orientation in the luciferase reporter plasmid pGL3. Vero cells were transfected and luciferase activity was monitored 24 h after transfection and the results show the mean of three independent parallels with SD. Similar results were obtained in two independent experiments. The luciferase activity of the archetypal promoter was arbitrarily set as 1.0 and the activities of the other promoters were related to the archetypal NCCR activity. The differences in early (respectively late) promoter activity of each variant tested compared to the early (respectively late) WW promoter activity are statistically significant (P,0.01).
BKPyV non-coding region in cerebrospinal fluid from CSF. Its NCCR consists of the linear OPQRS structure, but with deletions in the O-, P-, and R-blocks. These deletions remove several putative binding sites for transcription factors, but also create new sites for E47 and HSF1 (Table S3 ). The biological importance of these putative sites remains to be tested. Strains with similar NCCR structure as RRA to RRF have been described by others (Table S1) , but only one group tested the promoter activity of these isolates. Gosert and colleagues described several BKPyV isolates in renal transplant patients. Their variant del(R8-18) is almost identical to our RRA variant. While del(R8-18) had ytwofold higher early promoter activity and a late promoter activity that was less than 20 % of that of the archetypal WW strain (Gosert et al., 2008) , both early and late promoter activity of our RRA variant with deletion of R22-30 was weaker than WW. One obvious reason could be that deletion of R8-18 removes other putative binding sites or creates new sites at the R7-R19 junction than the R22-30 deletion (Table S3) . Another explanation may be that we used Vero cells, while Gosert and co-workers used HEK293 cells. Our RRF carries deletions of R15-63 plus S1-6, while del(13.8) isolated by . In accordance with their findings, we also found that our RRF had stronger early promoter activity. However, our RRF had comparable late promoter activity with the archetype, whereas del(13.8) presented weaker activity than the archetype. Of the strains with non-linear OPQRS anatomy, RRD resembles ins(4.5), ins(7.3) and ins(1483.5) described by Gosert et al. (2008) . These variants have duplication of Pblock nt 16-68, 21-53 and 8-58, respectively, while our RRD variant has duplication of P-block sequences 18-50. All four variants display an early promoter activity that is stronger than WW. However, ins(4.5) and ins(1483.5) had weaker, while ins(7.3) and RRD had stronger late promoter activity compared to WW.
Comparing the promoter activities of the rearranged NCCR from the CSF isolates with the activity of the archetypal NCCR in neuronal cells may reveal whether these rearranged promoters offer a replicative advantage to the virus. However, to the best of our knowledge, no permissive neuronal cell line for BKPyV has been described yet.
In summary, our findings demonstrate that BKPyV strains with the archetypal OPQRS NCCR anatomy as well as rearranged NCCR can be detected in CSF from neurological patients showing that rearrangements of NCCR per se are not sufficient to create neurotropic strains or to induce neuropathologies. Dissemination of a rearranged variant from the bloodstream to the brain does not seem to have initiated BKPyV infection in the CNS. However, early and late promoter activities of the rearranged neurological strains generally differed significantly from the archetype and most of them seemed to be stronger than the archetypal promoter. Therefore, because changes in VP1 have also been shown to affect BK replication (Dugan et al., 2007; Tremolada et al., 2010) , combination of VP1 polymorphism and rearranged NCCR may favour BKPyV replication in neural tissue.
METHODS
Patients and clinical samples. Between 1998 and 2010, 2406 CSF samples from neurological patients with suspected JCPyV infection were examined for BKPyV, JCPyV and SV40 LT-ag DNA at the National Centre of Microbiology by a qualitative multiplex nested PCR (Fedele et al., 1999) . LT-ag BKPyV DNA could be amplified from the CSF of 20 neurological patients, which were further investigated for the presence of BKPyV NCCR DNA. From some of those patients, other samples were available. A total of 27 CSF, 22 sera and one blood specimen from these patients were also analysed ( Table 1) . The presence of other neurological viruses in the CSF of these 20 patients, such as HSV, varicella-zoster virus, CMV, HHV6, EBV and human enteroviruses (including polio-, echo-and coxsackieviruses) was also determined by nested multiplex PCR (Casas et al., 1997) . The VP1 sequences from BKPyV variants in the CSF of 14 of these patients have been described previously (Bárcena-Panero et al., 2012) ( Table 1 ).
In addition, 43 blood and one serum sample from 44 renal transplant recipients and 17 urine, five blood and one serum specimen from six BMT recipients all of them previously positive for BKPyV LT-ag DNA in blood, were tested. Finally, 11 urine samples from 11 healthy pregnant women who were reported to excrete BKPyV DNA in urine were also analysed (Bendiksen et al., 2000) .
DNA isolation. DNA isolation was performed from 200 ml of sample using manual spin columns of QIAamp MinElute Virus Spin kit (Qiagen). DNA was eluted into a final volume of 20-45 ml nucleasefree water.
PCR amplification of NCCR sequences. Amplification of the BKPyV NCCR region was carried out by nested qualitative PCR. Two sets of primers were previously designed. For that purpose, 163 unique BKPyV complete genome sequences belonging to subtypes I-IV were obtained from GenBank and aligned with BioEdit software (Ibis Therapeutics). A first reaction was developed with: ORIBK1 (forward) 59-ATCTGGGCAAAGAGGAAAATCA-39 (nt 4881-4902 in BKPyV Dunlop strain GenBank extension V01108) and ORIBK2 (reverse) 59-AGCAGCCTCAGATACACTGG-39 (nt 661-680 in BKPyV Dunlop) primers. Nested PCR was performed with ORIBK3 (forward) 59-CAGGTTCCAAAATCAGGCTG-39 (nt 4924-4943 in Dunlop strain) and ORIBK4 (reverse) 59-CTAGGAGTCTTTTACA-GAGTCT-39 (nt 567-588 in Dunlop strain) primers. MgCl 2 , dNTPs, primer concentrations, as well as annealing and elongation temperatures were standardized in order to achieve the maximum sensitivity.
For both amplification reactions, AmpliTaq DNA polymerase with GeneAmp kit (Applied Biosystems) including 1.25 U of the polymerase was employed. A final volume of 50 ml was completed with 500 nM of each primer (or 200 nM of the nested reaction primers), 500 mM of dNTPs, 5 mM of MgCl 2 (or 3 mM for the nested PCR), nuclease-free water and 5 ml of the DNA eluted (or 2 ml of the first PCR product for the nested PCR).
Conditions consisted of a denaturation of 2 min at 94 uC and 30 cycles of 1 min at 94.9 uC (92 uC for the nested reaction), 1 min at 58.8 uC (58 uC for the nested reaction) and 1 min at 72 uC; and a final elongation step of 5 min at 72 uC.
Ten microlitres of each PCR sample was electrophoresed in a 1 % agarose gel prestained with ethidium bromide and visualized with UV fluorescence.
In all PCR experiments, positive (one BKPyV-positive urine sample) and negative controls (water) were included. To avoid contamination, ultrapure reagents were added under a laminar flow hood and different rooms, reagents and equipment were used for the DNA isolation, PCR set up and analysis.
A. Bá rcena-Panero and others
Sequencing of the nested PCR product. Amplified products were purified using the Wizard SV Gel and PCR Clean-Up System (Promega). Sequencing of both strands was carried out with the ABI Prism Big Dye Terminator Cycle Sequencing Ready kit (Applied Biosystems) and 1 mM of the nested primers. PCR conditions consisted of 3 min at 94 uC and 25 cycles of 10 s at 96 uC, 5 s at 50 uC and 4 min at 60 uC. Sequencing reactions were analysed on an ABI Prism 3700 DNA Analyser (Applied Biosystems).
Analysis of BKPyV NCCR sequences. Resulting sequences were aligned with the DNASTAR software v6 (Lasergene; DNASTAR Inc.) and compared to the reference strain WW (Moens & Van Ghelue, 2005) with BioEdit software (Ibis Therapeutics). To identify those sequences in the alignment that were unique, DnaSP v5 software (Librado & Rozas, 2009 ) was used.
Construction of luciferase reporter plasmid with the rearranged NCCR from the CSF BKPyV isolates. The complete NCCRs of the six rearranged neurological BKPyV variants RRA, RRB, RRC, RRD, RRE, RRF and the archetypal form WWM (obtained from the CSF of neurological patients NP5, NP7, NP11, NP12, NP17, NP20 and NP9, respectively) were amplified. PCR was performed in a volume of 30 ml using 150 ng of the primers that included HindIII restriction sites: NCCR F 59-CTAAGCTTTTGCAAAAATTGCA-AAAGAATAGG-39 (nt 1-26 in Dunlop strain) and NCCR R 59-GT-AAGCTTGGCCTTTGTCCAGTTTAACTG-39 (nt 367-387 in Dunlop strain). Reaction mix was completed with 15 ml Jumpstart (SigmaAldrich), 2 ml of the PCR product resulting from the amplification of the corresponding CSF samples with ORIBK1 and ORIBK2 primers that was employed as template and nuclease-free water. PCR conditions used were 5 min at 94 uC, 30 cycles of 30 s at 94 uC, 30 s at 55 uC, 30 s at 72 uC; and 7 min at 72 uC. PCR products were purified from the gel with a NucleoSpin Extract II kit (MachereyNagel) and cloned into a TOPO TA cloning kit with PCR 2.1-TOPO vector (Invitrogen). Resulting plasmids were purified using a QIAprep Spin Miniprep kit (Qiagen) and the presence of the inserts was confirmed by sequencing. The resulting plasmids were cleaved with HindIII (New England Biolabs) and ligated to the pGL3-basic vector containing the firefly luciferase gene (Promega) that was previously digested with HindIII and dephosphorylated with calf intestinal alkaline phosphatase (New England Biolabs). Ligation products were used to transform competent cells (Escherichia coli DH5a).
Resulting plasmids were purified as described above and the presence of the insert was confirmed by sequencing. Recombinant plasmids with inserts in both orientations were chosen in order to test the activity of both early and late NCCR promoters. DNA of positive constructs was purified by the NucleoBond Xtra Midi kit (MachereyNagel). Construction of the luciferase reporter plasmid with the early and late promoters of the Dunlop strain has been described previously .
Transfection of Vero cells. Vero African green monkey kidney cells (ATCC CCL-81) were cultured in Dulbecco's modified Eagle's medium (Invitrogen) with 10 % FBS (Invitrogen). Cells at approximately 60-70 % confluence in six-well plates were transfected with 4 mg of either pGL3-basic vector or the vector containing NCCR sequences. Transfection was carried out with 10 ml Lipofectamine 2000 (Invitrogen) following manufacturer's instructions. Medium was replaced after 4 h. Each experiment was repeated three times with three independent parallels.
Luciferase assays. Cells were lysed approximately 24 h posttransfection by using the Luciferase Assay Tropix Lysis solution (Applied Biosystems) as the manufacturer's instructions. Luciferase activity of each of the recombinant plasmids and the pGL3 basic control plasmid was calculated from the number of light units measured by a luminometer (Labsystem Luminoscan RT).
Statistical analysis. The statistical significance of the frequency of the rearrangements in the CSF of neurological patients regarding to other groups of patients was calculated with the Chi-squared test. Moreover, t-test was employed to determine statistical differences between the activity of the early and late promoters of each of the rearranged variants compared to the WW form.
